zolbetuximab + epirubicin + oxaliplatin + capecitabine

Zolbetuximab + epirubicin + oxaliplatin + capecitabine is a four-part drug regimen evaluated for **advanced gastric and gastroesophageal junction adenocarcinoma**. It combines: - **Zolbetuximab**, a chimeric monoclonal antibody that targets claudin 18.2 (CLDN18.2), a tight junction protein exclusively exposed on cancer cell surfaces in certain gastric and gastroesophageal cancers. Zolbetuximab mediates cell death mainly through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), attracting and activating immune cells to destroy cancer cells expressing CLDN18.2[1][2][4]. - **Epirubicin**, an anthracycline small molecule chemotherapeutic, inhibits topoisomerase II, intercalates into DNA, and induces apoptosis. - **Oxaliplatin**, a platinum-based small molecule chemotherapeutic, induces DNA cross-linking and cell death. - **Capecitabine**, an oral fluoropyrimidine small molecule prodrug converted to 5-fluorouracil (5-FU) in vivo, inhibits thymidylate synthase, disrupting DNA synthesis. This combination is often referred to as "ZOL/EOX" in clinical trials and showed significant improvements in progression-free survival and overall survival compared to chemotherapy alone in patients whose tumors overexpress CLDN18.2[3][5]. Zolbetuximab was developed by Astellas Pharma and branded as Vyloy[4].

Other names

zolbetuximab + EOX